A Reversal for GlycoMimetics, Inc. (GLYC) Is Not Near. The Stock Rises Again

Investors sentiment increased to 1.32 in 2019 Q1. Its up 0.26, from 1.06 in 2018Q4. It is positive, as 7 investors sold GlycoMimetics, Inc. shares while 21 reduced holdings. 10 funds opened positions while 27 raised stakes. 44.56 million shares or 0.36% more from 44.40 million shares in 2018Q4 were reported.
Susquehanna Intl Group Llp accumulated 19,361 shares or 0% of the stock. Deutsche Bancshares Ag accumulated 21,392 shares. Td Asset Management Incorporated reported 74,310 shares. Goldman Sachs Gp reported 0% in GlycoMimetics, Inc. (NASDAQ:GLYC). Daiwa Group Incorporated reported 0% in GlycoMimetics, Inc. (NASDAQ:GLYC). Manufacturers Life Ins The reported 23,481 shares. Dekabank Deutsche Girozentrale has invested 0% in GlycoMimetics, Inc. (NASDAQ:GLYC). Credit Suisse Ag invested in 24,526 shares or 0% of the stock. Moore Management Limited Partnership holds 50,000 shares or 0.02% of its portfolio. Fmr Lc has 3.90 million shares for 0.01% of their portfolio. Jgp Gestao De Recursos Ltda has 0.05% invested in GlycoMimetics, Inc. (NASDAQ:GLYC). Hudson Bay Capital Mngmt Limited Partnership has invested 0.04% of its portfolio in GlycoMimetics, Inc. (NASDAQ:GLYC). Citadel Advsr Ltd owns 738,665 shares for 0% of their portfolio. Alps Advisors Inc accumulated 104,192 shares. Commercial Bank Of America De owns 28,229 shares or 0% of their US portfolio.

The stock of GlycoMimetics, Inc. (NASDAQ:GLYC) is a huge mover today! The stock increased 4.81% or $0.14 during the last trading session, reaching $3.05. About 1.71 million shares traded or 113.04% up from the average. GlycoMimetics, Inc. (NASDAQ:GLYC) has declined 32.63% since August 15, 2018 and is downtrending. It has underperformed by 32.63% the S&P500.
The move comes after 5 months positive chart setup for the $131.74M company. It was reported on Aug, 15 by Barchart.com. We have $3.17 PT which if reached, will make NASDAQ:GLYC worth $5.27M more.

GlycoMimetics, Inc. (NASDAQ:GLYC) Ratings Coverage

Among 3 analysts covering GlycoMimetics (NASDAQ:GLYC), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. GlycoMimetics has $23 highest and $500 lowest target. $11.33’s average target is 271.48% above currents $3.05 stock price. GlycoMimetics had 9 analyst reports since February 28, 2019 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, March 7 by H.C. Wainwright. Piper Jaffray downgraded GlycoMimetics, Inc. (NASDAQ:GLYC) rating on Monday, August 5. Piper Jaffray has “Neutral” rating and $600 target. The rating was downgraded by SunTrust on Monday, August 5 to “Hold”.

More notable recent GlycoMimetics, Inc. (NASDAQ:GLYC) news were published by: Benzinga.com which released: “The Daily Biotech Pulse: Sanofi’s Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering – Benzinga” on August 06, 2019, also Nasdaq.com with their article: “Health Care Sector Update for 08/05/2019: GLYC, PRVB, ZYME, JNJ, PFE, ABT, MRK, AMGN – Nasdaq” published on August 05, 2019, Seekingalpha.com published: “GlycoMimetics’ lead drug flunks late-stage study; shares down 54% premarket – Seeking Alpha” on August 05, 2019. More interesting news about GlycoMimetics, Inc. (NASDAQ:GLYC) were released by: Businesswire.com and their article: “GlycoMimetics to Report Second Quarter 2019 Financial Results on August 1, 2019 – Business Wire” published on July 25, 2019 as well as Seekingalpha.com‘s news article titled: “Global Blood Therapeutics: A Promising Biotech Pick In 2019 – Seeking Alpha” with publication date: July 29, 2019.

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company has market cap of $131.74 million. The firm is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. It currently has negative earnings. It is also developing GMI-1359, a drug candidate targeting E-selectin and CXCR4; and galectin-3 and galectin-9 inhibitors.

GlycoMimetics, Inc. (NASDAQ:GLYC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.